权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

Molecular Mechanisms Regulated by FOXM1 in Chronic Lung Remodeling

FOXM1在慢性肺重塑中调控的分子机制

基本信息

批准号：
10891764
负责人：
Vladimir Kalinichenko
金额：
$ 48.98万
依托单位：
UNIVERSITY OF ARIZONA
依托单位国家：
美国
项目类别：
财政年份：
2023
资助国家：
美国
起止时间：
2023-07-21 至 2024-05-31
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/10891764
关键词：
Molecular Mechanisms Regulated FOXM1 Chronic

项目摘要

PROJECT SUMMARY. COPD is a severe chronic respiratory disease, which is associated with smoking and characterized by chronic lung inflammation, emphysema, airway remodeling and goblet cell metaplasia. Identification of new molecular targets is needed to improve therapeutic outcomes in COPD patients. Our grant application will explore the role of Forkhead transcription factor FOXM1 as a potential therapeutic target in mouse and rat COPD models. FOXM1 is an embryonic transcription factor, which is not expressed in quiescent lungs but aberrantly induced during lung carcinogenesis. We provide preliminary data demonstrating that FOXM1 is activated in airway epithelial cells, macrophages and type II cells of COPD patients and mice exposed to cigarette smoke (CS). Increased expression of FOXM1 in mouse and human lungs is associated with emphysema and goblet cell metaplasia. Transgenic overexpression of FOXM1 in alveolar type II cells exacerbated lung inflammation, leading to emphysema. Genetic deletion of Foxm1 gene from myeloid cells, including macrophages and monocytes, decreased pulmonary inflammation after acute lung injury. Genetic ablation of Foxm1 from airway club cells decreased goblet cell metaplasia caused by house dust mite allergens. While FOXM1 is increased in human COPD and mouse genetic data suggest that FOXM1 is critical goblet cell metaplasia, pulmonary inflammation and alveolar remodeling, molecular mechanisms regulated by FOXM1 in COPD remain unknown. We propose to test the hypothesis that FOXM1 increases goblet cell metaplasia and emphysema in COPD by transcriptionally activating distinct sets of pro-inflammatory and mucinous genes in alveolar type II cells, airway club cells and macrophages. We will also test the therapeutic efficacy of novel FOXM1 inhibitor RCM-1 in mouse and rat COPD models. Chronic CS exposure and a combination of CS and Influenza infection will be used to induce pulmonary inflammation, emphysema and goblet cell metaplasia. In Aim 1, we will identify molecular mechanisms regulated by FOXM1 in alveolar type II cells (Aim 1A) and macrophages (Aim 1B) using purified cells and mice with specific ablation of Foxm1 gene from these cell types. FOXM1 targets will be validated using de-identified human COPD lungs. In Aim 2A, we will use mice with specific deletion of Foxm1 from airway club cells, to identify FOXM1 target genes critical for differentiation of club cells into goblet cells in COPD model. In Aim 2B, we will test therapeutic potential of novel, non-toxic FOXM1-inhibiting small molecule compound, RCM-1, which has been recently discovered in my lab using a high throughput screen. Altogether, these studies will identify novel molecular mechanisms critical for COPD pathogenesis and test therapeutic potential of FOXM1 inhibitors in animal COPD models.

项目摘要。COPD是一种严重的慢性呼吸道疾病，与吸烟和其特征在于慢性肺部炎症、肺气肿、气道重塑和杯状细胞化生。需要鉴定新的分子靶点以改善COPD患者的治疗结果。我们的资助应用将探索叉头转录因子FOXM 1作为潜在治疗靶点的作用，小鼠和大鼠COPD模型。FOXM 1是一种胚胎转录因子，在胚胎发育中不表达。静止的肺，但在肺癌发生过程中异常诱导。我们提供的初步数据表明， FOXM 1在COPD患者和小鼠的气道上皮细胞、巨噬细胞和II型细胞中被激活，香烟烟雾（CS）。小鼠和人肺中FOXM 1表达增加与肺气肿和杯状细胞化生肺泡II型细胞中FOXM 1的转基因过表达加剧了肺部炎症导致肺气肿骨髓细胞中Foxm 1基因的遗传缺失，包括巨噬细胞和单核细胞，减少急性肺损伤后的肺部炎症。遗传去除气道俱乐部细胞Foxm 1减少屋尘螨引起的杯状细胞化生过敏原虽然FOXM 1在人类COPD中增加，但小鼠遗传数据表明FOXM 1是至关重要的。杯状细胞化生，肺部炎症和肺泡重塑， FOXM 1在COPD中的作用尚不清楚。我们建议测试FOXM 1增加杯状细胞的假设，通过转录激活不同的促炎性和肺泡II型细胞、气道俱乐部细胞和巨噬细胞中的粘液基因。我们还将测试新型FOXM 1抑制剂RCM-1在小鼠和大鼠COPD模型中功效。慢性CS暴露和 CS和流感病毒感染的组合将用于诱导肺部炎症、肺气肿和杯状细胞化生在目标1中，我们将确定II型肺泡中FOXM 1调节的分子机制细胞（Aim 1A）和巨噬细胞（Aim 1B），使用纯化的细胞和小鼠特异性切除Foxm 1基因这些细胞类型。FOXM 1靶标将使用去识别的人COPD肺进行验证。在目标2A中，我们将使用从气道俱乐部细胞中特异性缺失Foxm 1的小鼠，以鉴定FOXM 1靶基因， COPD模型中棒状细胞向杯状细胞的分化。在目标2B中，我们将测试一种新的、无毒的FOXM 1抑制小分子化合物，RCM-1，最近在我的实验室用的是高通量筛选。总之，这些研究将确定新的分子机制，关键的COPD发病机制和测试FOXM 1抑制剂在动物COPD模型中的治疗潜力。

项目成果

期刊论文数量（19）

专著数量（0）

科研奖励数量（0）

会议论文数量（0）

专利数量（0）

Novel FOXF1-Stabilizing Compound TanFe Stimulates Lung Angiogenesis in Alveolar Capillary Dysplasia.

新型 FOXF1 稳定化合物 TanFe 刺激肺泡毛细血管发育不良的肺血管生成。

DOI：
10.1164/rccm.202207-1332oc
发表时间：
2023
期刊：
American journal of respiratory and critical care medicine
影响因子：
24.7
作者：
Pradhan,Arun;Che,Lixiao;Ustiyan,Vladimir;Reza,AbidA;Pek,NicoleM;Zhang,Yufang;Alber,AndreaB;Kalin,TimothyR;Wambach,JenniferA;Gu,Mingxia;Kotton,DarrellN;Siefert,MatthewE;Ziady,AssemG;Kalin,TanyaV;Kalinichenko,VladimirV
通讯作者：
Kalinichenko,VladimirV

Genome Editing for Rare Diseases.

DOI：
10.1007/s40778-020-00175-1
发表时间：
2020-09
期刊：
Current stem cell reports
影响因子：
1.4
作者：
Pradhan A;Kalin TV;Kalinichenko VV
通讯作者：
Kalinichenko VV

Generation of Pulmonary Endothelial Progenitor Cells for Cell-based Therapy Using Interspecies Mouse-Rat Chimeras.

使用种间小鼠-大鼠嵌合体生成肺内皮祖细胞用于基于细胞的治疗。

DOI：
10.1164/rccm.202003-0758oc
发表时间：
2021
期刊：
American journal of respiratory and critical care medicine
影响因子：
24.7
作者：
Wang,Guolun;Wen,Bingqiang;Ren,Xiaomeng;Li,Enhong;Zhang,Yufang;Guo,Minzhe;Xu,Yan;Whitsett,JeffreyA;Kalin,TanyaV;Kalinichenko,VladimirV
通讯作者：
Kalinichenko,VladimirV

Nanoparticle Delivery of STAT3 Alleviates Pulmonary Hypertension in a Mouse Model of Alveolar Capillary Dysplasia.

DOI：
10.1161/circulationaha.121.053980
发表时间：
2021-08-17
期刊：
Circulation
影响因子：
37.8
作者：
Sun F;Wang G;Pradhan A;Xu K;Gomez-Arroyo J;Zhang Y;Kalin GT;Deng Z;Vagnozzi RJ;He H;Dunn AW;Wang Y;York AJ;Hegde RS;Woods JC;Kalin TV;Molkentin JD;Kalinichenko VV
通讯作者：
Kalinichenko VV

FOXF1 is required for the oncogenic properties of PAX3-FOXO1 in rhabdomyosarcoma.

DOI：
10.1038/s41388-021-01694-9
发表时间：
2021-03
期刊：
Oncogene
影响因子：
8
作者：
Milewski D;Shukla S;Gryder BE;Pradhan A;Donovan J;Sudha P;Vallabh S;Pyros A;Xu Y;Barski A;Szabo S;Turpin B;Pressey JG;Millay DP;Khan J;Kalinichenko VV;Kalin TV
通讯作者：
Kalin TV